HHS is terminating a contract with drugmaker Moderna to develop a vaccine to protect against bird flu amid the agency's broader efforts to reevaluate therapies that use mRNA technology. The contract, which was worth $590 million, was announced in mid-January, just before President Donald Trump's second term. Moderna said Wednesday that an early-phase trial of its mRNA-based vaccine against H5 bird flu in about 300 healthy adults showed "a rapid, potent and durable immune response."
